Entwicklung der Adipositas in Deutschland - Größenordnung, Determinanten und Perspektiven

Prugger, Christof; Keil, U

doi:10.1055/s-2007-973636

Cited by 43 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, they are mostly based on cross-sectional data and may therefore only draw conclusions regarding short-term associations of BMI and expenditures. Yet, obesity is also related to increased risk factors for several diseases that might occur with a significant time lag [14,15]. Information on the long-term influence of elevated BMI on health care expenditures and the role of weight development or maintenance is still scarce.…”

Section: Introductionmentioning

confidence: 99%

Impact of BMI and BMI change on future drug expenditures in adults: results from the MONICA/KORA cohort study

Teuner

Menn

Heier

et al. 2013

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundThe evidence on the long-term economic effects of obesity is still scarce. This study aims to analyse the impact of body mass index (BMI) and BMI-change on future pharmaceutical utilisation and expenditures.MethodsBased on data from 2,946 participants in a German population-based health survey (MONICA/KORA, 1994/95) and the follow-up study (2004/05), drug intake and expenditures were estimated using a bottom-up approach. Using univariate and multivariate methods, we analysed the impact of baseline BMI and BMI-change on drug utilisation and expenditures after 10 years.ResultsThe use of pharmaceuticals was more likely in moderately and severely obese compared to the normal weight group (OR 1.8 and 4.0, respectively). In those who reported pharmaceutical intake, expenditures were about 40% higher for the obese groups. A 1-point BMI-gain in 10 years was, on average, associated with almost 6% higher expenditures compared to a constant BMI.ConclusionThe results suggest that obesity as well as BMI-gain are strong predictors of future drug utilisation and associated expenditures in adults, and thus highlight the necessity of timely and effective intervention and prevention programmes. This study complements the existing literature and provides important information on the relevance of obesity as a health problem.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of BMI and BMI change on future drug expenditures in adults: results from the MONICA/KORA cohort study

Teuner

Menn

Heier

et al. 2013

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…Key words: general practitioner, prevention, overweight, risk counseling, qualitative research, check-up examination Einleitung Ü bergewicht und Adipositas nehmen in der deutschen Bevö lkerung in den letzten Jahren zu [1,2]. Das Robert Koch Institut scha¨tzt, dass weniger als die Hä lfte der weiblichen und nur ein Drittel der mä nnlichen Bevö lkerung normalgewichtig sind [3].…”

Section: Discussionunclassified

Übergewichtige Patienten in der Hausarztpraxis: Wie wird die Gesundheitsuntersuchung zur Risikoberatung genutzt?

Heintze

Metz

Wiesner

et al. 2009

Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheit

View full text Add to dashboard Cite

“…Overweight and obesity in adulthood are recognised as important risk factors for numerous chronic diseases [3]. Obesity in childhood also increases the risk of later morbidities [4,5] and in turn increases the risk of obesity in adulthood [6].…”

Section: Introductionmentioning

confidence: 99%

Juvenile obesity and its association with utilisation and costs of pharmaceuticals - results from the KiGGS study

Wenig

Knopf

Menn

2011

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundAccording to a national reference, 15% of German children and adolescents are overweight (including obese) and 6.3% are obese. An earlier study analysed the impact of childhood overweight and obesity on different components of direct medical costs (physician, hospital and therapists). To complement the existing literature for Germany, this study aims to explore the association of body mass index (BMI) with utilisation of pharmaceuticals and related costs in German children and adolescents.MethodsBased on data from 14, 836 respondents aged 3-17 years in the German Interview and Examination Survey for Children and Adolescents (KiGGS), drug intake and associated costs were estimated using a bottom-up approach. To investigate the association of BMI with utilisation and costs, univariate analyses and multivariate generalised mixed models were conducted.ResultsThere was no significant difference between BMI groups regarding the probability of drug utilisation. However, the number of pharmaceuticals used was significantly higher (14%) for obese children than for normal weight children. Furthermore, there was a trend for more physician-prescribed medication in obese children and adolescents. Among children with pharmaceutical intake, estimated costs were 24% higher for obese children compared with the normal weight group.ConclusionsThis is the first study to estimate excess drug costs for obesity based on a representative cross-sectional sample of the child and adolescent population in Germany. The results suggest that obese children should be classified as a priority group for prevention. This study complements the existing literature and provides important information concerning the relevance of childhood obesity as a health problem.

show abstract

Entwicklung der Adipositas in Deutschland - Größenordnung, Determinanten und Perspektiven

Cited by 43 publications

References 18 publications

Impact of BMI and BMI change on future drug expenditures in adults: results from the MONICA/KORA cohort study

Impact of BMI and BMI change on future drug expenditures in adults: results from the MONICA/KORA cohort study

Übergewichtige Patienten in der Hausarztpraxis: Wie wird die Gesundheitsuntersuchung zur Risikoberatung genutzt?

Juvenile obesity and its association with utilisation and costs of pharmaceuticals - results from the KiGGS study

Contact Info

Product

Resources

About